Abstract
Ginsenoside metabolite compound K (CK) is the degradation product of ginsenosides in the intestine by bacteria and has many pharmacological activities including anti-inflammatory effects. Rheumatoid arthritis (RA) is an inflammatory and autoimmune disease characterized by chronic synovial inflammation and articular damage in multiple joints. However, the effect of CK on RA remains unclear. In this study, the effect of CK on adjuvant arthritis (AA) and the underlying mechanisms that focused on T cell activation were investigated. Complete Freund’s adjuvant was used to induce AA rats. After the onset of arthritis, rats were given CK (10, 40, and 160 mg/kg) or MTX (0.5 mg/kg). To evaluate the severity of arthritis, arthritis index and paw swelling were evaluated every 3 days. Histopathology of joint and spleen were assayed. Subsets of T cells including CD4 + CD62L+ (naïve T cells), CD4 + CD25+ (activated T cells), and CD4 + CD25 + Foxp3+ cells (Treg) and CD25 expression were assayed by flow cytometry. Proliferation of T cell was evaluated by 3H-TdR. IL-2 level was assayed by ELISA. We found that CK attenuated arthritis index and paw swelling, restored the histopathological change of joint and spleen, downregulated the percentage of activated T cells, and upregulated naïve T cells and Treg cells in spleen. CK significantly suppressed T cell activation (as indicated by T cell proliferation, CD25 expression, and IL-2 production). In conclusion, our results suggest that CK alleviates autoimmune arthritis by suppressing T cell activation.
REFERENCES
Carmona, L., M. Cross, B. Williams, M. Lassere, and L. March. 2010. Rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 24(6): 733–745.
Rodeghero, R., Y. Cao, S.A. Olalekan, Y. Iwakua, T.T. Glant, and A. Finnegan. 2013. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. Journal of Immunology 190(11): 5423–5435.
Lundy, S.K., S. Sarkar, L.A. Tesmer, and D.A. Fox. 2007. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research and Therapy 9(1): 202.
Rogers, J.L., D.S. Serafin, R.G. Timoshchenko, and T.K. Tarrant. 2012. Cellular targeting in autoimmunity. Current Allergy and Asthma Reports 12(6): 495–510.
Martin, R. 2012. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clinical Immunology 142(1): 9–14.
Chang, Y., Y. Wu, D. Wang, W. Wei, Q. Qin, G. Xie, L. Zhang, S. Yan, J. Chen, Q. Wang, H. Wu, F. Xiao, W. Sun, J. Jin, and W. Wang. 2011. Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford) 50(5): 862–870.
Song, S.S., B. Huang, Q.T. Wang, Y.J. Wu, J.J. Fu, Y.F. Zhang, Y. Chang, J.Y. Chen, H.X. Wu, D. Wang, L.L. Zhang, and W. Wei. 2013. BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats. Acta Pharmacologica Sinica 34(3): 414–423.
Chi, H., and G.E. Ji. 2005. Transformation of ginsenosides Rb1 and Re from Panax ginseng by food microorganisms. Biotechnological Letters 27(11): 765–771.
Tawab, M.A., U. Bahr, M. Karas, M. Wurglics, and M. Schubert-Zsilavecz. 2003. Degradation of ginsenosides in humans after oral administration. Drug Metabolism and Disposition 31(8): 1065–1071.
Joh, E.H., I.A. Lee, I.H. Jung, and D.H. Kim. 2011. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochemical Pharmacology 82(3): 278–286.
Park, E.K., Y.W. Shin, H.U. Lee, S.S. Kim, Y.C. Lee, B.Y. Lee, and D.H. Kim. 2005. Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biological and Pharmaceutical Bulletin 28(4): 652–656.
Yang, C.S., S.R. Ko, B.G. Cho, D.M. Shin, J.M. Yuk, S. Li, J.M. Kim, R.M. Evans, J.S. Jung, D.K. Song, and E.K. Jo. 2008. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. Journal of Cellular and Molecular Medicine 12(5A): 1739–1753.
Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344(12): 907–916.
Létourneau, S., C. Krieg, G. Pantaleo, and O. Boyman. 2009. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Journal of Allergy and Clinical Immunology 123(4): 758–762.
Laurence, A., C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, and J.J. O'shea. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3): 371–381.
Cote-Sierra, J., G. Foucras, L. Guo, L. Chiodetti, H.A. Young, J. Hu-Li, J. Zhu, and W.E. Paul. 2004. Interleukin 2 plays a central role in Th2 differentiation. Proceedings of the National Academy of Sciences of the United States of America 101(11): 3880–3885.
Kovanen, P.E., and W.J. Leonard. 2004. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunological Reviews 202: 67–83.
Dooms, H., E. Kahn, B. Knoechel, and A.K. Abbas. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. Journal of Immunology 172(10): 5973–5979.
Dooms, H., K. Wolslegel, P. Lin, and A.K. Abbas. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. Journal of Experimental Medicine 204(3): 547–557.
Brok, H.P., J.M. Tekoppele, J. Hakimi, J.A. Kerwin, E.M. Nijenhuis, C.W. De Groot, R.E. Bontrop, and B.A. ‘t Hart. 2001. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clinical and Experimental Immunology 124(1): 134–141.
Mijnheer, G., B.J. Prakken, and F. van Wijk. 2013. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Current Opinion in Rheumatology 25(2): 260–267.
Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. Journal of Experimental Medicine 200(3): 277–285.
Buckner, J.H. 2010. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 10: 849–859.
Frey, O., P.K. Petrow, M. Gajda, K. Siegmund, J. Huehn, A. Scheffold, A. Hamann, A. Radbruch, and R. Bräuer. 2005. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Research and Therapy 7(2): R291–R301.
Kong, N., Q. Lan, M. Chen, T. Zheng, W. Su, J. Wang, Z. Yang, R. Park, G. Dagliyan, P.S. Conti, D. Brand, Z. Liu, H. Zou, W. Stohl, and S.G. Zheng. 2012. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Annals of the Rheumatic Diseases 71(9): 1567–1572.
Shevach, E.M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5): 636–645.
Wing, K., Z. Fehérvári, S. Sakaguchi, K. Wing, Z. Fehervari, and S. Sakaguchi. 2006. Emerging possibilities in the development and function of regulatory T cells. International Immunology 18(7): 991–1000.
Wu, H., J. Chen, Q. Wang, X. Jia, S. Song, P. Yuan, K. Liu, L. Liu, Y. Zhang, A. Zhou, and W. Wei. 2014. Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats. Immunopharmacology and Immunotoxicology
ACKNOWLEDGMENTS
This work was financially supported by the National Nature Science Foundation of China (Nos. 30973543, 81173075, 81330081, and 31200675), Anhui Province Nature Science Foundation in the University (No. KJ2011Z180), Foundation for Outstanding Young Talents in Higher Education Institutions of Anhui Province (No. 2012SQRL268), and Anhui Provincial Natural Science Foundation (No. 1208085QH158).
Conflict of Interest
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, J., Wu, H., Wang, Q. et al. Ginsenoside Metabolite Compound K Alleviates Adjuvant-Induced Arthritis by Suppressing T Cell Activation. Inflammation 37, 1608–1615 (2014). https://doi.org/10.1007/s10753-014-9887-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-014-9887-0